MCID: TGV001
MIFTS: 14

Togaviridae Disease

Categories: Rare diseases

Aliases & Classifications for Togaviridae Disease

MalaCards integrated aliases for Togaviridae Disease:

Name: Togaviridae Disease 54
Togaviridae Infections 74
Togaviridae Infection 54
Togavirus Infections 54

Classifications:



External Ids:

UMLS 74 C0040361

Summaries for Togaviridae Disease

MalaCards based summary : Togaviridae Disease, also known as togaviridae infections, is related to chikungunya. The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder.

Wikipedia : 77 Togaviridae is a family of viruses. Humans, mammals, birds, and mosquitoes serve as natural hosts. There... more...

Related Diseases for Togaviridae Disease

Diseases related to Togaviridae Disease via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 chikungunya 10.1

Symptoms & Phenotypes for Togaviridae Disease

Drugs & Therapeutics for Togaviridae Disease

Drugs for Togaviridae Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
4
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
5
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
6 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
7 Hemagglutinins Phase 3
8 Somatomedin B Phase 3
9 taxane Phase 3
10 Antirheumatic Agents Phase 3,Not Applicable
11 Anti-Infective Agents Phase 3,Phase 1,Phase 2
12 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Not Applicable
13 Anti-Inflammatory Agents Phase 3,Not Applicable
14 Vitamins Phase 3
15 Antioxidants Phase 3
16 Trace Elements Phase 3
17 Micronutrients Phase 3
18 Protective Agents Phase 3
19 Nutrients Phase 3
20 Retinol palmitate Phase 3
21 retinol Phase 3
22 Antiprotozoal Agents Phase 3
23 Analgesics, Non-Narcotic Phase 3
24 Peripheral Nervous System Agents Phase 3
25 Anthelmintics Phase 3
26 Chloroquine diphosphate Phase 3 50-63-5
27 Antimalarials Phase 3
28 Antiparasitic Agents Phase 3
29 Analgesics Phase 3
30
Altretamine Approved Phase 2 645-05-6 2123
31
Tetracycline Approved, Vet_approved Phase 1, Phase 2 60-54-8 5353990
32
Aluminum sulfate Approved Phase 2,Phase 1 10043-01-3
33
Aluminum hydroxide Approved, Investigational Phase 2,Phase 1 21645-51-2
34 Antibodies Phase 1, Phase 2,Phase 2,Not Applicable
35 Immunoglobulins, Intravenous Phase 1, Phase 2
36 Immunoglobulins Phase 1, Phase 2,Phase 2,Not Applicable
37 Rho(D) Immune Globulin Phase 1, Phase 2
38 gamma-Globulins Phase 1, Phase 2
39 Anti-Bacterial Agents Phase 1, Phase 2
40 Gastrointestinal Agents Phase 1
41 Antacids Phase 1
42 Anti-Ulcer Agents Phase 1
43 Adjuvants, Immunologic Phase 1
44 Antibodies, Monoclonal Phase 1
45
Mechlorethamine Approved, Investigational Not Applicable 51-75-2 4033
46
Methylprednisolone Approved, Vet_approved Not Applicable 83-43-2 6741
47
Prednisolone Approved, Vet_approved Not Applicable 50-24-8 5755
48
Methotrexate Approved Not Applicable 1959-05-2, 59-05-2 126941
49
leucovorin Approved Not Applicable 58-05-9 143 6006
50
Pantoprazole Approved Not Applicable 102625-70-7 4679

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Unknown status NCT03071575 Phase 4
2 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Completed NCT03368495 Phase 4
3 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
4 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
5 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
6 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
7 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
8 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
9 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
10 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
11 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
12 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
13 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
14 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
15 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
16 MMR at 6 Months Trial Recruiting NCT03780179 Phase 4
17 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
18 Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III) Completed NCT03713359 Phase 3
19 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines Completed NCT00984295 Phase 3
20 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed NCT00566527 Phase 3
21 ProQuad® Intramuscular vs Subcutaneous Completed NCT00402831 Phase 3
22 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) Completed NCT00109343 Phase 3
23 A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) Completed NCT00092391 Phase 3
24 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
25 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
26 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
27 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
28 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
29 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
30 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
31 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
32 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
33 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed NCT00985166 Phase 3
34 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3
35 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
36 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
37 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
38 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3
39 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed NCT00483574 Phase 3
40 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed NCT00432042 Phase 3
41 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3
42 Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine Completed NCT00406211 Phase 3
43 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed NCT00384397 Phase 3
44 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
45 Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes Completed NCT00351923 Phase 3
46 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
47 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
48 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
49 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
50 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3

Search NIH Clinical Center for Togaviridae Disease

Genetic Tests for Togaviridae Disease

Anatomical Context for Togaviridae Disease

Publications for Togaviridae Disease

Articles related to Togaviridae Disease:

# Title Authors Year
1
Characterization of the immune response following in vitro mayaro and chikungunya viruses (Alphavirus, Togaviridae) infection of mononuclear cells. ( 30145137 )
2018

Variations for Togaviridae Disease

Expression for Togaviridae Disease

Search GEO for disease gene expression data for Togaviridae Disease.

Pathways for Togaviridae Disease

GO Terms for Togaviridae Disease

Sources for Togaviridae Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....